BioScrip Inc (NASDAQ:BIOS), on May 8, 2014 announced 2014 first quarter financial results. First quarter revenue from continuing operations was $239.6 million and the net loss from continuing operations was $25.4 million, or $0.37 per basic and diluted share. Non-GAAP adjusted loss from continuing operations per basic and diluted share was $0.13.BioScrip Inc (NASDAQ:BIOS) stock performance was 17.08% in last session and finished the day … Continue reading Healthcare Gainers: BioScrip Inc (NASDAQ:BIOS), NPS Pharmaceuticals (NASDAQ:NPSP), RadNet Inc. (NASDAQ:RDNT), Avanir Pharmaceuticals Inc (NASDAQ:AVNR)